FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667024> ?p ?o ?g. }

• W4385667024 endingPage "e1342620" @default.
• W4385667024 startingPage "e1342620" @default.
• W4385667024 abstract "Topic: 16. Myeloproliferative neoplasms - Clinical Background: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disease characterized by persistent monocytosis, splenomegaly, and both dysplastic and myeloproliferative changes in the bone marrow. Hypomethylating agents are approved for CMML treatment as they have historically been included in pivotal studies, however only account for ~10% of trial patients. ASTX727, an orally available fixed dose combination (FDC) of 35 mg decitabine (DEC) and 100 mg cedazuridine (CED), a cytidine deaminase inhibitor, produces comparable PK AUC exposure compared to intravenous decitabine (Garcia-Manero, et al, 2019). Aims: We present the combined clinical experience of patients with CMML in the critical studies leading to FDA approval of oral DEC/CED (ClinicalTrilas.gov NCT02103478 and NCT03306264, respectively) with additional analysis of genetic profiles for the subset. Methods: 33 CMML patients (16 from phase 2, and 17 from phase 3) who were candidates for parenteral decitabine with PS 0-2 were enrolled and received standard oral decitabine/cedazuridine FDC for 5 days. Clinical endpoints were best response according to International Working Group (IWG) 2006 response criteria, transfusion independence for at least 8 or 16 consecutive weeks, leukemia free survival (LFS), overall survival (OS), and safety. Peripheral blood collected prior to treatment was used for DNA isolation from leukocytes, and molecular abnormalities identified using a NGS hematologic malignancy panel, including 8 genes frequently associated with CMML. Cox-regression analysis on the various factors (eg binary mutational status, CR, etc.) was used for analyses of risk-factors for OS. Results: Median age was 71 years, with 55% patients with ECOG PS of 1. One-third of patients were RBC transfusion-dependent at baseline. 70% of patients were subtyped as CMML-1 based on the 2022 WHO classification, and 76% patients had MD-CMML. The median number of mutations in CMML patients was 3 (range 0-5) among 8 commonly mutated genes (see Figure 1). 85% of patients had received no prior anticancer therapy for CMML. Patients received a median of 10 cycles of therapy (range 2-36). Seven patients (21.2%) had Complete Responses (CR), 14 (42.4%) had marrow CR (mCR), including 5 (15.2%) who also had hematologic improvement (HI). Overall response rate (ORR) [CR + PR+ mCR + HI] was 75.8%. 63.6% of those dependent on red blood cell (RBC) transfusions at baseline became transfusion independent (TI) for at least 8 weeks and 45.5% for 16 weeks. Median LFS was 28.3 months and median OS was 35.7 months. Safety profile is consistent with decitabine, with most grade 3 or higher events related to myelosuppression; Treatment-emergent adverse events of CTCAE Grade 3 or higher in > 10% of patients, independent of relationship to ASTX727, were cytopenias (neutropenia [61%], thrombocytopenia [55%], anemia [36%], febrile neutropenia [27%], and leukopenia [24%]). Given the advanced age of the CMML cohort, only 3 (9%) went on to Hematopoietic Stem Cell Transplant. Cox regression analysis suggested that post-treatment RBC TI seemed to be associated with survival; no apparent effect on OS was observed for other baseline or response-related factors, including baseline genetic variants, such as ASXL1 among others (Figure 1) though the sensitivity of such analysis is limited by the number of patients. Summary/Conclusion: DEC/CED has a well-tolerated safety profile with clinical benefit in CMML patients. Preliminary analysis suggests an association between TI and longer survival.Keywords: Oral, Chronic myelomonocytic leukemia, CMML, Hypomethylating agents" @default.
• W4385667024 created "2023-08-09" @default.
• W4385667024 creator A5001695445 @default.
• W4385667024 creator A5001745177 @default.
• W4385667024 creator A5002099817 @default.
• W4385667024 creator A5006561610 @default.
• W4385667024 creator A5008422091 @default.
• W4385667024 creator A5009167813 @default.
• W4385667024 creator A5010523200 @default.
• W4385667024 creator A5010962133 @default.
• W4385667024 creator A5012863731 @default.
• W4385667024 creator A5023965566 @default.
• W4385667024 creator A5034756815 @default.
• W4385667024 creator A5035609080 @default.
• W4385667024 creator A5036678244 @default.
• W4385667024 creator A5041470459 @default.
• W4385667024 creator A5043321505 @default.
• W4385667024 creator A5043492753 @default.
• W4385667024 creator A5044632878 @default.
• W4385667024 creator A5049400849 @default.
• W4385667024 creator A5052288829 @default.
• W4385667024 creator A5055906478 @default.
• W4385667024 creator A5057987415 @default.
• W4385667024 creator A5058326151 @default.
• W4385667024 creator A5060015628 @default.
• W4385667024 creator A5060452476 @default.
• W4385667024 creator A5061026876 @default.
• W4385667024 creator A5063696834 @default.
• W4385667024 creator A5065584610 @default.
• W4385667024 creator A5066224233 @default.
• W4385667024 creator A5067521829 @default.
• W4385667024 creator A5067973814 @default.
• W4385667024 creator A5082283453 @default.
• W4385667024 date "2023-08-01" @default.
• W4385667024 modified "2023-10-15" @default.
• W4385667024 title "P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES" @default.
• W4385667024 doi "https://doi.org/10.1097/01.hs9.0000969844.13426.20" @default.
• W4385667024 hasPublicationYear "2023" @default.
• W4385667024 type Work @default.
• W4385667024 citedByCount "0" @default.
• W4385667024 crossrefType "journal-article" @default.
• W4385667024 hasAuthorship W4385667024A5001695445 @default.
• W4385667024 hasAuthorship W4385667024A5001745177 @default.
• W4385667024 hasAuthorship W4385667024A5002099817 @default.
• W4385667024 hasAuthorship W4385667024A5006561610 @default.
• W4385667024 hasAuthorship W4385667024A5008422091 @default.
• W4385667024 hasAuthorship W4385667024A5009167813 @default.
• W4385667024 hasAuthorship W4385667024A5010523200 @default.
• W4385667024 hasAuthorship W4385667024A5010962133 @default.
• W4385667024 hasAuthorship W4385667024A5012863731 @default.
• W4385667024 hasAuthorship W4385667024A5023965566 @default.
• W4385667024 hasAuthorship W4385667024A5034756815 @default.
• W4385667024 hasAuthorship W4385667024A5035609080 @default.
• W4385667024 hasAuthorship W4385667024A5036678244 @default.
• W4385667024 hasAuthorship W4385667024A5041470459 @default.
• W4385667024 hasAuthorship W4385667024A5043321505 @default.
• W4385667024 hasAuthorship W4385667024A5043492753 @default.
• W4385667024 hasAuthorship W4385667024A5044632878 @default.
• W4385667024 hasAuthorship W4385667024A5049400849 @default.
• W4385667024 hasAuthorship W4385667024A5052288829 @default.
• W4385667024 hasAuthorship W4385667024A5055906478 @default.
• W4385667024 hasAuthorship W4385667024A5057987415 @default.
• W4385667024 hasAuthorship W4385667024A5058326151 @default.
• W4385667024 hasAuthorship W4385667024A5060015628 @default.
• W4385667024 hasAuthorship W4385667024A5060452476 @default.
• W4385667024 hasAuthorship W4385667024A5061026876 @default.
• W4385667024 hasAuthorship W4385667024A5063696834 @default.
• W4385667024 hasAuthorship W4385667024A5065584610 @default.
• W4385667024 hasAuthorship W4385667024A5066224233 @default.
• W4385667024 hasAuthorship W4385667024A5067521829 @default.
• W4385667024 hasAuthorship W4385667024A5067973814 @default.
• W4385667024 hasAuthorship W4385667024A5082283453 @default.
• W4385667024 hasBestOaLocation W43856670241 @default.
• W4385667024 hasConcept C104317684 @default.
• W4385667024 hasConcept C126322002 @default.
• W4385667024 hasConcept C143998085 @default.
• W4385667024 hasConcept C150194340 @default.
• W4385667024 hasConcept C185592680 @default.
• W4385667024 hasConcept C190727270 @default.
• W4385667024 hasConcept C2777928532 @default.
• W4385667024 hasConcept C2778461978 @default.
• W4385667024 hasConcept C2780007613 @default.
• W4385667024 hasConcept C2780235182 @default.
• W4385667024 hasConcept C2780240888 @default.
• W4385667024 hasConcept C2780817109 @default.
• W4385667024 hasConcept C2781087989 @default.
• W4385667024 hasConcept C55493867 @default.
• W4385667024 hasConcept C71924100 @default.
• W4385667024 hasConcept C90924648 @default.
• W4385667024 hasConceptScore W4385667024C104317684 @default.
• W4385667024 hasConceptScore W4385667024C126322002 @default.
• W4385667024 hasConceptScore W4385667024C143998085 @default.
• W4385667024 hasConceptScore W4385667024C150194340 @default.
• W4385667024 hasConceptScore W4385667024C185592680 @default.
• W4385667024 hasConceptScore W4385667024C190727270 @default.
• W4385667024 hasConceptScore W4385667024C2777928532 @default.
• W4385667024 hasConceptScore W4385667024C2778461978 @default.
• W4385667024 hasConceptScore W4385667024C2780007613 @default.

• next